share_log

Beam Therapeutics analyst ratings

Beam Therapeutics analyst ratings

BEAM治療公司分析師評級
Benzinga Analyst Ratings ·  2022/05/09 13:14
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
05/09/2022 250.22% SVB Leerink $118 → $121 Maintains Outperform
04/28/2022 79.45% Credit Suisse → $62 Initiates Coverage On → Neutral
01/10/2022 250.22% SVB Leerink $116 → $121 Maintains Outperform
01/05/2022 276.27% Guggenheim → $130 Initiates Coverage On → Buy
11/09/2021 235.75% SVB Leerink $117 → $116 Maintains Outperform
10/19/2021 238.64% SVB Leerink → $117 Initiates Coverage On → Outperform
09/10/2021 334.15% B of A Securities → $150 Initiates Coverage On → Buy
06/29/2021 331.26% Wedbush $114 → $149 Maintains Outperform
05/11/2021 — Redburn Partners Initiates Coverage On → Buy
05/04/2021 146.02% RBC Capital → $85 Initiates Coverage On → Sector Perform
03/01/2021 160.49% Barclays $47 → $90 Downgrades Overweight → Equal-Weight
02/16/2021 319.68% Wells Fargo → $145 Initiates Coverage On → Overweight
01/29/2021 189.44% JP Morgan $38 → $100 Downgrades Overweight → Neutral
01/06/2021 143.13% Stifel → $84 Initiates Coverage On → Hold
08/05/2020 -4.49% William Blair → $33 Initiates Coverage On → Outperform
03/02/2020 -7.38% Wedbush → $32 Initiates Coverage On → Outperform
03/02/2020 -7.38% Barclays → $32 Initiates Coverage On → Overweight
03/02/2020 -7.38% Jefferies → $32 Initiates Coverage On → Buy
日期 上行/下行 分析公司 目標價格變化 評級變化 上一次/當前評級
05/09/2022 250.22% SVB Leerink $118 → $121 維護 跑贏大盤
04/28/2022 79.45% 瑞士信貸 → $62 開始承保 →中性
01/10/2022 250.22% SVB Leerink $116 → $121 維護 跑贏大盤
01/05/2022 276.27% 古根海姆 → $130 開始承保 →購買
11/09/2021 235.75% SVB Leerink $117 → $116 維護 跑贏大盤
10/19/2021 238.64% SVB Leerink → $117 開始承保 →跑贏大盤
09/10/2021 334.15% B of A證券 → $150 開始承保 →購買
06/29/2021 331.26% 韋德布什 $114 → $149 維護 跑贏大盤
05/11/2021 — Redburn合作伙伴 開始承保 →購買
05/04/2021 146.02% 加拿大皇家銀行資本 → $85 開始承保 →行業表現
03/01/2021 160.49% 巴克萊 $47 → $90 評級下調 超重→等重
02/16/2021 319.68% 富國銀行(Wells Fargo) → $145 開始承保 →超重
01/29/2021 189.44% 摩根大通 $38 → $100 評級下調 超重→中性
01/06/2021 143.13% Stifel → $84 開始承保 →保留
08/05/2020 -4.49% 威廉·布萊爾 → $33 開始承保 →跑贏大盤
03/02/2020 -7.38% 韋德布什 → $32 開始承保 →跑贏大盤
03/02/2020 -7.38% 巴克萊 → $32 開始承保 →超重
03/02/2020 -7.38% 傑富瑞 → $32 開始承保 →購買
Data brought to you by Benzinga APIs
Benzinga API為您帶來的數據

Beam Therapeutics Questions & Answers

BEAM治療學問答

What is the target price for Beam Therapeutics (BEAM)?
BEAM治療(BEAM)的目標價格是多少？

The latest price target for Beam Therapeutics (NASDAQ: BEAM) was reported by SVB Leerink on May 9, 2022. The analyst firm set a price target for $121.00 expecting BEAM to rise to within 12 months (a possible 250.22% upside). 9 analyst firms have reported ratings in the last year.

BEAM治療公司(納斯達克代碼：BEAM)的最新目標價是由SVB Leerink於2022年5月9日報道的。這家分析公司將目標價定為121.00美元，預計BEAM將在12個月內上漲至250.22美元(可能上漲250.22%)。去年有9家分析公司公佈了評級。

What is the most recent analyst rating for Beam Therapeutics (BEAM)?
光束治療公司(BEAM)的最新分析師評級是什麼？

The latest analyst rating for Beam Therapeutics (NASDAQ: BEAM) was provided by SVB Leerink, and Beam Therapeutics maintained their outperform rating.

比姆治療公司(納斯達克代碼：BEAM)的最新分析師評級由SVB Leerink提供，比姆治療公司維持其表現優於大盤的評級。

When is the next analyst rating going to be posted or updated for Beam Therapeutics (BEAM)?
束流療法(BEAM)的下一次分析師評級將於何時發佈或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Beam Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Beam Therapeutics was filed on May 9, 2022 so you should expect the next rating to be made available sometime around May 9, 2023.

分析師在進行了廣泛的研究後得出了股票評級，其中包括查閲公共財務報表，與比姆治療公司的高管和客户交談，以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。BEAM治療公司的上一次評級是在2022年5月9日提交的，所以你應該預計下一次評級將在2023年5月9日左右提供。

Is the Analyst Rating Beam Therapeutics (BEAM) correct?
分析師對光束治療公司(BEAM)的評級正確嗎？

While ratings are subjective and will change, the latest Beam Therapeutics (BEAM) rating was a maintained with a price target of $118.00 to $121.00. The current price Beam Therapeutics (BEAM) is trading at is $34.55, which is out of the analyst's predicted range.

雖然評級是主觀的，並將發生變化，但最新的光束治療公司(BEAM)評級保持不變，目標價在118.00美元至121.00美元之間。BEAM目前的交易價格為34.55美元，超出了分析師的預測範圍。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論